SEC Form 4 · accession 0001267490-26-000006
Serina Therapeutics, Inc. · SER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen J Wilson
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 10:31 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001708599
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | P | 5,100 | $1.745 | A | 5,100 | D | |
| Common StockF2 | Jun 12, 2026 | P | 5,000 | $1.77 | A | 10,100 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.
- F2The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.